Telomerase activity in microdissected human gliomas

Robert J. Weil, Yan Yun Wu, Alexander Vortmeyer, Young Wan Moon, Rosario M. Delgado, Brian G. Fuller, Russell R. Lonser, Alan T. Remaley, Zhengping Zhuang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Future improvements in the diagnosis and treatment of human gliomas might rely on obtaining more specific information concerning the biologic characteristics of individual tumor cells. Telomerase, a ribonucleoprotein that synthesizes telomeres, has been reported to be expressed in a majority of human tumors, including several subtypes of brain tumor. We hypothesized that a quantitative assay for telomerase activity, combined with selective microdissection of tumor or normal brain cells, might reveal telomerase gain- of-function to be important in the pathogenesis of gliomas and that telomerase levels might have prognostic significance. We used tissue microdissection for selective analysis of tumor cells obtained from eight patients with glioma, one with a meningioma, and one with a primary B-cell lymphoma of the central nervous system. Normal brain tissue microdissected from another patient was used as a control. Telomerase activity was screened by an electrophoretic method and then assayed by a quantitative ELISA method. All of the eight gliomas had positive telomerase activity, as did the lymphoma. The meningioma and normal brain were negative. Quantitative analysis of telomerase activity did not correlate with tumor grade nor predict outcome. Selective tissue microdissection, combined with qualitative and quantitative telomerase assays, permits rapid and reliable detection of telomerase activity in diverse brain tumor tissues. These preliminary findings suggest that telomerase reactivation is a frequent event in glioma tumorigenesis that can be sensitively and specifically detected in gliomas of all histologic grades. Furthermore, specific detection of telomerase reactivation represents another mechanism by which tumor formation and progression might become the target of novel therapeutics.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalModern Pathology
Volume12
Issue number1
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Telomerase
Glioma
Microdissection
Neoplasms
Meningioma
Brain Neoplasms
Brain
Ribonucleoproteins
Telomere
B-Cell Lymphoma
Lymphoma
Carcinogenesis
Central Nervous System
Enzyme-Linked Immunosorbent Assay

Keywords

  • Astrocytoma
  • ELISA
  • Glioblastoma multiforme
  • Meningioma
  • Oligodendroglioma
  • Telomere

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Weil, R. J., Wu, Y. Y., Vortmeyer, A., Moon, Y. W., Delgado, R. M., Fuller, B. G., ... Zhuang, Z. (1999). Telomerase activity in microdissected human gliomas. Modern Pathology, 12(1), 41-46.

Telomerase activity in microdissected human gliomas. / Weil, Robert J.; Wu, Yan Yun; Vortmeyer, Alexander; Moon, Young Wan; Delgado, Rosario M.; Fuller, Brian G.; Lonser, Russell R.; Remaley, Alan T.; Zhuang, Zhengping.

In: Modern Pathology, Vol. 12, No. 1, 01.01.1999, p. 41-46.

Research output: Contribution to journalArticle

Weil, RJ, Wu, YY, Vortmeyer, A, Moon, YW, Delgado, RM, Fuller, BG, Lonser, RR, Remaley, AT & Zhuang, Z 1999, 'Telomerase activity in microdissected human gliomas', Modern Pathology, vol. 12, no. 1, pp. 41-46.
Weil RJ, Wu YY, Vortmeyer A, Moon YW, Delgado RM, Fuller BG et al. Telomerase activity in microdissected human gliomas. Modern Pathology. 1999 Jan 1;12(1):41-46.
Weil, Robert J. ; Wu, Yan Yun ; Vortmeyer, Alexander ; Moon, Young Wan ; Delgado, Rosario M. ; Fuller, Brian G. ; Lonser, Russell R. ; Remaley, Alan T. ; Zhuang, Zhengping. / Telomerase activity in microdissected human gliomas. In: Modern Pathology. 1999 ; Vol. 12, No. 1. pp. 41-46.
@article{5556fad498664e588ca813e0645159d3,
title = "Telomerase activity in microdissected human gliomas",
abstract = "Future improvements in the diagnosis and treatment of human gliomas might rely on obtaining more specific information concerning the biologic characteristics of individual tumor cells. Telomerase, a ribonucleoprotein that synthesizes telomeres, has been reported to be expressed in a majority of human tumors, including several subtypes of brain tumor. We hypothesized that a quantitative assay for telomerase activity, combined with selective microdissection of tumor or normal brain cells, might reveal telomerase gain- of-function to be important in the pathogenesis of gliomas and that telomerase levels might have prognostic significance. We used tissue microdissection for selective analysis of tumor cells obtained from eight patients with glioma, one with a meningioma, and one with a primary B-cell lymphoma of the central nervous system. Normal brain tissue microdissected from another patient was used as a control. Telomerase activity was screened by an electrophoretic method and then assayed by a quantitative ELISA method. All of the eight gliomas had positive telomerase activity, as did the lymphoma. The meningioma and normal brain were negative. Quantitative analysis of telomerase activity did not correlate with tumor grade nor predict outcome. Selective tissue microdissection, combined with qualitative and quantitative telomerase assays, permits rapid and reliable detection of telomerase activity in diverse brain tumor tissues. These preliminary findings suggest that telomerase reactivation is a frequent event in glioma tumorigenesis that can be sensitively and specifically detected in gliomas of all histologic grades. Furthermore, specific detection of telomerase reactivation represents another mechanism by which tumor formation and progression might become the target of novel therapeutics.",
keywords = "Astrocytoma, ELISA, Glioblastoma multiforme, Meningioma, Oligodendroglioma, Telomere",
author = "Weil, {Robert J.} and Wu, {Yan Yun} and Alexander Vortmeyer and Moon, {Young Wan} and Delgado, {Rosario M.} and Fuller, {Brian G.} and Lonser, {Russell R.} and Remaley, {Alan T.} and Zhengping Zhuang",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
volume = "12",
pages = "41--46",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Telomerase activity in microdissected human gliomas

AU - Weil, Robert J.

AU - Wu, Yan Yun

AU - Vortmeyer, Alexander

AU - Moon, Young Wan

AU - Delgado, Rosario M.

AU - Fuller, Brian G.

AU - Lonser, Russell R.

AU - Remaley, Alan T.

AU - Zhuang, Zhengping

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Future improvements in the diagnosis and treatment of human gliomas might rely on obtaining more specific information concerning the biologic characteristics of individual tumor cells. Telomerase, a ribonucleoprotein that synthesizes telomeres, has been reported to be expressed in a majority of human tumors, including several subtypes of brain tumor. We hypothesized that a quantitative assay for telomerase activity, combined with selective microdissection of tumor or normal brain cells, might reveal telomerase gain- of-function to be important in the pathogenesis of gliomas and that telomerase levels might have prognostic significance. We used tissue microdissection for selective analysis of tumor cells obtained from eight patients with glioma, one with a meningioma, and one with a primary B-cell lymphoma of the central nervous system. Normal brain tissue microdissected from another patient was used as a control. Telomerase activity was screened by an electrophoretic method and then assayed by a quantitative ELISA method. All of the eight gliomas had positive telomerase activity, as did the lymphoma. The meningioma and normal brain were negative. Quantitative analysis of telomerase activity did not correlate with tumor grade nor predict outcome. Selective tissue microdissection, combined with qualitative and quantitative telomerase assays, permits rapid and reliable detection of telomerase activity in diverse brain tumor tissues. These preliminary findings suggest that telomerase reactivation is a frequent event in glioma tumorigenesis that can be sensitively and specifically detected in gliomas of all histologic grades. Furthermore, specific detection of telomerase reactivation represents another mechanism by which tumor formation and progression might become the target of novel therapeutics.

AB - Future improvements in the diagnosis and treatment of human gliomas might rely on obtaining more specific information concerning the biologic characteristics of individual tumor cells. Telomerase, a ribonucleoprotein that synthesizes telomeres, has been reported to be expressed in a majority of human tumors, including several subtypes of brain tumor. We hypothesized that a quantitative assay for telomerase activity, combined with selective microdissection of tumor or normal brain cells, might reveal telomerase gain- of-function to be important in the pathogenesis of gliomas and that telomerase levels might have prognostic significance. We used tissue microdissection for selective analysis of tumor cells obtained from eight patients with glioma, one with a meningioma, and one with a primary B-cell lymphoma of the central nervous system. Normal brain tissue microdissected from another patient was used as a control. Telomerase activity was screened by an electrophoretic method and then assayed by a quantitative ELISA method. All of the eight gliomas had positive telomerase activity, as did the lymphoma. The meningioma and normal brain were negative. Quantitative analysis of telomerase activity did not correlate with tumor grade nor predict outcome. Selective tissue microdissection, combined with qualitative and quantitative telomerase assays, permits rapid and reliable detection of telomerase activity in diverse brain tumor tissues. These preliminary findings suggest that telomerase reactivation is a frequent event in glioma tumorigenesis that can be sensitively and specifically detected in gliomas of all histologic grades. Furthermore, specific detection of telomerase reactivation represents another mechanism by which tumor formation and progression might become the target of novel therapeutics.

KW - Astrocytoma

KW - ELISA

KW - Glioblastoma multiforme

KW - Meningioma

KW - Oligodendroglioma

KW - Telomere

UR - http://www.scopus.com/inward/record.url?scp=0032934447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032934447&partnerID=8YFLogxK

M3 - Article

C2 - 9950161

AN - SCOPUS:0032934447

VL - 12

SP - 41

EP - 46

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 1

ER -